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The potential of tumor three-dimensional (3D) in vitro models for the validation of existing
or novel anti-cancer therapies has been largely recognized. During the last decade,
diverse in vitro 3D cell systems have been proposed as a bridging link between two-
dimensional (2D) cell cultures and in vivo animal models, both considered gold standards
in pre-clinical settings. The latest awareness about the power of tailored therapies and
cell-based therapies in eradicating tumor cells raises the need for versatile 3D cell culture
systems through which we might rapidly understand the specificity of promising anti-
cancer approaches. Yet, a faithful reproduction of the complex tumor microenvironment is
demanding as it implies a suitable organization of several cell types and extracellular matrix
components. The proposed 3D tumor models discussed here are expected to offer the
required structural complexity while also assuring cost-effectiveness during pre-selection
of the most promising therapies. As neuroblastoma is an extremely heterogenous
extracranial solid tumor, translation from 2D cultures into innovative 3D in vitro systems
is particularly challenging. In recent years, the number of 3D in vitro models mimicking
native neuroblastoma tumors has been rapidly increasing. However, in vitro platforms that
efficiently sustain patient-derived tumor cell growth, thus allowing comprehensive drug
discovery studies on tailored therapies, are still lacking. In this review, the latest
neuroblastoma 3D in vitro models are presented and their applicability for a more
accurate prediction of therapy outcomes is discussed.
Keywords: 3D in vitro models, neuroblastoma, pediatric oncology, immunotherapy, drug screening,
extracellular matrixINTRODUCTION
The turn of the 20th century was crucial for the development of the basic principles for in vitro cell
growth enabled substantial biological discoveries. Over time, the complexity of in vitro systems has
increased according to the needs of various branches of life science. The enhancement of in vitro
techniques applicable in these two-dimensional (2D) systems greatly changed the perception of cell-
related processes and allowed more accurate deciphering of the fundamental biomolecular and
biophysical mechanisms active in both, physiological conditions and disease (1). The 21st Century
brought great progress in the development of the existing in vitro models for the study of moreorg November 2020 | Volume 11 | Article 5842141
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approaching as much as possible in vivo situations (2). A major
tendency toward replacing, reducing, and refining (3R) animal use
took place, supporting the application of the 3R principle for in
vivo experimentation and energizing the development of diverse
3D cell culture technologies (3). This development represents the
achievements of a breakthrough in the field of tissue engineering
and regenerative biomedicine. Other disciplines of life science
adopted the advances of available 3D models for addressing
specific challenges and pitfalls encountered in the use of 2D
systems, while also outlining novel considerations of cell and
tissue-related questions.
In oncology, the introduction of 3D models for investigating
tumor biology and cancer cells behavior is rapidly increasing.
However, the standard procedures in this research still mainly
follow a conventional route of initial testing in a Petri dish (2D)
followed by in vivo validations in zebrafish, mice, or other small
laboratory animals (4). The highly standardized protocols, well-
established experimental approaches, and low costs of 2D tumor
models explain the high rate of their application regardless of
limited accuracy in representing native neoplastic tissues and
predicting physiological values. The major obstacle to a
straightforward translation of in vitro biological process
analyzed in 2D conditions into an in vivo response is the lack
of multicellular systems that are in direct contact with the cell-
extracellular matrix (ECM) components (5). The tumor
microenvironment (TME) is formed of several different cell
types and non-cellular components (ECM). TME allows
malignant cells to grow in 3D conditions, making the system
extremely dynamic and complex. Yet, the proper architecture,
tumor stiffness and relaxation behavior are not adequately
considered in 2D in vitro studies, leading to limited
information about the realistic changes in signaling pathways,
metabolic activities, and genetic/epigenetic backgrounds of
tumor and stromal cells (6, 7). The transition from 2D to in
vivo pharmacological testing during the early stages of drug
examination is therefore often critical but without the desired
level of success (8). Many efforts are currently attempting to
bridge the gap between 2D and in vivo systems by proposing
different 3D in vitro models in which cell line and primary cells
can be grown in either static or dynamic conditions.
Even though 3D cell culture techniques can minimize these
limitations, their widespread use is still limited due to the
relatively high costs, complexity of preparation, and lack of
standardized protocols that can guarantee high reproducibility
and unequivocal data interpretation (9). Unsurprisingly, 2D cell
cultures and in vivo animal models are still considered the gold
standards in pre-clinical settings in oncology. However, the
traditional means of drug efficacy evaluation faces serious
limitations, since many compounds that show good anti-
cancer effects in murine models fail to provide meaningful
clinical benefits for humans (10). Therefore, this scenario is
changing in the direction of 3D models more often being built
of primary cells as the protagonist of anti-neoplastic drug
screening. This trend is also supported by important
innovations in live cell in vitro imaging techniques thatFrontiers in Immunology | www.frontiersin.org 2accelerate drug discovery (11). Still, most of these proposals
come from cancers developing in adults, whereas there is a clear
deficit of a pre-clinical 3D model providing analysis of drug
response in pediatric tumors. This is particularly evident for
neuroblastoma, for which a vast majority of scientific questions
are still answered by using either 2D studies or the transgenic and
xenograft zebrafish and murine models (12–14).
Neuroblastoma is an embryonal malignancy of the
sympathetic nervous system with very heterogeneous biologic,
morphologic, genetic, and clinical characteristics. It is classified
as a neuroblastic tumor but in contrast to ganglioneuroblastoma
and ganglioneuroma, neuroblastoma is more aggressive (15).
Based on several clinical and molecular risk factors each
patient is stratified in one of the following risk groups: very-
low, low, intermediate or high-risk (16). Such a pre-treatment
risk group assignment facilitates treatment modalities as well
(17). In high-risk patients, the aggressive course of the
malignancy manifests as a disseminated disease (stage 4) with
metastatic processes in the liver, bone marrow and bone, skin
and several other organs (18). The treatment of these patients
represents one of the most urgent challenges for oncologists.
Despite intensive multimodal therapy, in more than 50% of high-
risk patients, the disease progresses during the course of therapy
leading to a fatal outcome (19).
Recent studies have shed light on the biology of neuroblastoma
allowing a more accurate stratification of patients into risk groups,
resulting in a reduction of treatment cytotoxicity without affecting
the outcome of low and intermediate-risk patients (20, 21).
However, the mortality rate of children in high-risk group is still
high, and the development of more valuable therapeutic strategies
remains urgent. During the last few years, different approaches
such as transcriptomics analyses and genome-wide association
studies have listed the genes associated with neuroblastoma
susceptibility, aggressiveness, and progression (22, 23). The
identification of such genes has raised the possibility of
developing novel targeted therapies or reconsidering already
existing drugs by the repositioning of FDA-approved drugs.
In this review, the latest in vitro 3D models suitable for
assessing drug-specific responses in neuroblastoma will be
addressed. We will discuss their implications in pre-clinical
testing and applicability for a more accurate prediction of
therapy outcomes. Finally, the possibilities of introducing
already available bioengineered platforms and devices for the
generation of predictive neuroblastoma models will be explored.
We will assess current possibilities for a more accurate in vitro
investigation of the pharmacotherapeutic cues in this tumor to
justify clinical trials.NEUROBLASTOMA IN VITRO 3D MODELS
The lack of reliable in vitro tumor platforms for rapid and highly
reproducible studies in cancer biology has driven the
development of new tumor models by applying various
bioengineering methodologies. Although these models share a
common 3D conformation, each displays its own intrinsicNovember 2020 | Volume 11 | Article 584214
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that the proliferation of tumor cells is significantly less when
compared with 2D growth conditions (12, 24). In the following
paragraphs, we will address the current applications of 3D in
vitro culture systems in the neuroblastoma research field.
Multicellular Tumor Spheroids (MCTSs)
MCTS is themost well-characterized 3Dmodel for cancer research
obtainedbygrowing cancercell linesunder lowadherent conditions
(25). MCTSs can have different configurations depending on the
specific aim of the study: they can be composed of a single or
multiple cell types, generated either through the aggregation and
compaction of multiple cells in suspension, or by establishing cell
masses from a single cell via consecutive cell doublings. In either of
these cases biomimetic ECM support, playing the role of a scaffold,
may or may not be applied (12, 26).
MCTSs obtained by the aggregation of neuroblastoma cell lines
represent an attractive tool to reproduce in vitro the in vivo
characteristics of tumor cells with respect to the production of
ECM, cell–cell interactions, growth kinetics, cellular heterogeneity,
signal pathway activity, and gene expression (13, 25). Given the
importance of the cell-ECM interaction in a 3D extent, among the
most studied behaviors in the neuroblastoma field are the
migratory and invasive potentials of cancer cells. For example,
the analysis of different neuroblastoma cell lines embedded in 3D
collagen gels revealed the relationship between cellular
morphology (elongated/mesenchymal versus amoeboid/rounded
cells) and their invasive capability through a surrounding
environment (27). The main difference between the cells grown
in 2D and 3D collagen structures is recognized in the Rac signaling
pathway, which is differently expressed in these structures. It is a
crucial regulator of cell invasion from the spheroid body through
the surrounding matrix (27). These results highlight that
biochemical signals in the neuroblastoma cells may change
dramatically in response to changes in their spatio-temporal
distribution. Moreover, they strengthen the case for using 3D
systems to select the compounds able to counteract invasion of
neuroblastoma cells. In addition to single chemical testing,
neuroblastoma spheroids are also suitable for investigating the
role of specific proteins on neuroblastoma outgrowth. For
example, high levels of Stathmin (a Tubulin binding protein) are
associated with tumor aggression and the appearance of metastatic
disease. This protein has been selected by analyzing cell line-
derived MCTSs where it contributes to a higher invasive motility
of the cells (28). Besides Stathmin, SNAI2 is also a crucial
molecular determinant of invasive tumor strands. This protein
defines the border regularity of the MCTSs and promotes local 3D
invasion and dissemination of neuroblastoma cells (29).
However, some critical issues related to cell line-derived
MCTSs need to be considered. The variability in spheroid size
and their inhomogeneous density profoundly affect the response
to drug treatments. As a consequence, this feature negatively
impacts the reproducibility and reliability of the obtained results
(26). In addition, long-term in vitro culture of cell line-derived
MCTSs is very challenging since these structures lack a stem cell
population able to self-renew the spheroid necrotic core.
Moreover, this model is not able to faithfully approximate/Frontiers in Immunology | www.frontiersin.org 3simulate the complexity of neuroblastoma genetics and the
tumor microenvironment found in humans.
Tissue-Derived Tumor Spheres (TDTSs)
TDTSs are obtained by tumor tissue mechanical dissociation
(26). Due to the origin of primary cells, this in vitromodel system
more closely reflects the genetic and clonal heterogeneity of the
native tumor, thus providing a more accurate pre-clinical
platform (30). Despite the fact that these tailored models can
lead to an improved level of prediction, their development and
application are still a challenge as sample collection and size,
protocol standardization and data reproducibility are critical issues
for neuroblastoma. More easily established are neuroblastoma-
derived spheroids generated from the bone marrow aspirates of
patients diagnosed with stage 4 metastatic disease (30). In some
cases, surgically removed tumor resections also allow in vitro
reproduction of neuroblastoma. However, at the moment it is hard
to predict which clinico-biological criterion is a determining factor
in enabling the successful in vitro growth of a single specimen (31).
In fact, a success rate of 55% has been reported for neurosphere
maintenance in vitro. Also, the expansion of neurospheres cannot
be linearly predicted from patient clinic data such as age, stage,
MYCN amplification and the presence of segmental chromosomal
aberrations (31). While the characterization of the resulting
neurospheres is currently limited to the expression of CD56 and
GD2 neuroblastoma markers, their importance relies on the
presentation of reproducible protocols for the in vitro expansion
of often limited amounts of tumor tissue specimens. Screening for
additional antigens specific for neuroblastoma is, however,
necessary for more accurate selection of tumor cells with stem
features that are often responsible for drug resistance development
and disease recurrence. Another TDTS model resembling
neuroblastoma intratumoral heterogeneity has been reported by
Thole and colleagues (30). The primary neuroblastoma TDTSs
culture derived from a bone marrow aspirate with 80% tumor cell
infiltration can be cultured in Matrigel. Neuroblastoma cells
grown as 3D spheroids maintain the tumorigenic capability in a
xenotransplantation mouse model through five passages.
Importantly, these TDTSs model systems partly reflect the
genetic and clonal heterogeneity of the initial biopsy (30).
Altogether, the reported neuroblastoma TDTSs represent
essential initial steps toward more sophisticated 3D
neuroblastoma modeling suitable for pre-clinical testing.
Patient-Derived Tumor Organoids (PDTOs)
Organoids are in vitro derived 3D cell aggregates that are capable
of self-renewal and self-organization, while exhibiting expected
organ functionality. Organoids are usually generated from either
embryonic stem cells (ECS) or induced pluripotent stem cells
(iPSC) (32). To date, several organoids have been established for
many cancer types (reviewed in ref. (33)).
PDTOs cultures show strong phenotypical and genetic
similarities to the original tumor, enabling their use across a
wide spectrum of applications. PDTOs allow long-term culture
and cryopreservation for the generation of patient-derived tumor
organoid biobanks (34). However, most of the patient-derived
cancer organoids have an epithelial origin. The generation ofNovember 2020 | Volume 11 | Article 584214
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from other non-epithelial cancers, remains today a major
challenge in organoid technology.MOVING FROM 2D TOWARD 3D
PRE-CLINICAL SETTINGS
In general, we are currently faced with an extremely low efficacy of
pre-clinical studies. In oncology, less than 10%of drugs successfully
conclude clinical trials (35), resulting in significant time and
economic loss. The introduction of high-throughput drug
screening (HTS) speeds up target identification and lead
compound selection, increasing the number of anti-neoplastic
compounds that potentially reach clinical trial (36). As stated
above, the majority of HTS studies are based on the use of tumor
cell lines grown in 2D conditions. This approach is slowly being
reconsidered and comprises the introduction of different 3D
cultures in order to increase the likelihood of pre-clinical success
(Figure 1). In neuroblastoma, the number of studies that have
examined 3D spheroids for HTS is relatively low and their
introduction is a challenge. This is particularly true for 3D
structures containing patient-derived primary cells due to a lack
of study material and difficulties to culture and maintain them
in vitro.
Each tumor can be considered as a heterogeneous structure
deriving from the interaction between cancer cells and the
surrounding microenvironment, which provides important
physical and biochemical signals for its growth. The information
coming from the native 3D human cancer structure can affect, for
example, the expression of specific genes as well as the diffusion of
nutrients and oxygen within the tumor mass. Moreover, thisFrontiers in Immunology | www.frontiersin.org 4complex network of interactions determines the ability of tumor
cells to resist and escape from pharmacological treatments. This
diversity could be at the root of treatment failures, which remain a
peril in the neuroblastoma field today.
Pioneering 3D Neuroblastoma Models for
Drug Screening Studies
In order to address these needs, 3D culture technology has been
applied in the testing of the sensitivity of several MCTSs to
doxorubicin exposure, confirming the modification in tolerance
to this drug when moving from 2D to 3D culture systems (37).
Moreover, MCTSs obtained with the SH-SY5Y neuroblastoma cell
line shows higher sensitivity to rapamycin and triciribine when
compared to the correspondent 2D culture, emphasizing the
importance of in vitro 3D models as a valid system for initial
testing of new anti-cancer agents (38). In a recent work aimed at
identifying candidate drugs for repositioning in high-risk patients,
HTS of a library of anticancer compounds was tested in
neuroblastoma MCTSs (39). This study proposes MCTSs
viability validation using a high-content imaging approach as a
powerful and reliable 3D platform to predict pre-clinical efficacies
and to reproduce drug responses of neuroblastoma tumors.BIOMIMETIC EXTRACELLULAR
MATRIX (ECM) SUPPORTS FOR
NEUROBLASTOMA TUMOR MODEL
FABRICATION
The ECM represents a dynamic and versatile network of secreted
proteins and polysaccharides assembled together in an organizedFIGURE 1 | Scheme of the HTS (high throughput drug screening) method. HTS is used to evaluate multiple morphological and cellular parameters in a high number
of MCTSs (multicellular tumor spheroids) grown and treated inside microplates. The drug treatment is combined with an optical (upper image) and fluorescence
(lower image) microscopy systems for automated image acquisition and coupled analyses through specific software pipelines. These platforms make suitable
automatic quantitative analyses of the 3D culture systems in response to drug administration.November 2020 | Volume 11 | Article 584214
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homeostasis (40). The ECM provides structural support to all
organs and provides a substrate upon which cells can migrate.
Moreover, the interaction between cells and the ECM
macromolecules plays an essential role in tuning the behavior
of many cell types in a physiological context. Indeed, during
embryonic development the ECM provides essential extrinsic
signals for the correct migration of neural crest cells, the
pluripotent stem cell population from which neuroblastoma
may arise (41).
Role of ECM in Neuroblastoma
The ECM has a complex and tissue-specific molecular
composition. The dynamic remodeling of the ECM is of
outmost importance in order to determine the specificity of its
biological functions during organogenesis and to guarantee a
proper tissue homeostasis. As a consequence, the disruption of
such mechanisms disorganizes the extracellular niche, leading to
abnormal behaviors of resident cells and the failure of tissue
homeostasis. Indeed, dysregulation of ECM composition,
architecture and stiffness leads toward development or
worsening of several diseases, including fibrosis and cancer
(42). A large body of experimental evidence emphasizes how
ECM proteins promote tumor metastasis and modulate the
maintenance and expansion of several cancer cell types and
metastatic niches (reviewed in ref. (43–45)).
In neuroblastoma, the presence of a stromal component
positively correlates with tumor maturation and favorable
prognosis (46). In addition, the deposition of specific ECM
components defines an ultra-high risk group of patients affected
by neuroblastoma, suggesting that the quantification of tumor
stroma components by morphometric techniques could be a
valuable tool in improving patients’ risk stratification (47). From
the molecular perspective, several studies have demonstrated how
the cross-talk between neuroblastoma cells and the ECM
influences cancer cell differentiation (48). More recently, besides
the molecular signaling activated through the cell-ECM
interaction, the biomechanical properties of the ECM, such as
stiffness and deformability, have also been recognized as
mechanical modulators of cancer cell behavior (49). Indeed,
dissecting the role of the ECM within the neuroblastoma niche
may provide insight into new mechanobiological cues influencing
tumor growth and differentiation. This knowledge would provide
the basis for future work aimed at the design and exploitation of
novel therapeutic strategies against neuroblastoma.
Cast In Vitro 3D Models for Studying
Neuroblastoma
As mentioned, after important tumor-related knowledge was
obtained from 2D cell systems, the importance of introducing
ECM component as important determinant of tumor cells
behavior pushed the boundaries beyond the second dimension
(50). This led to the incorporation of the achievements obtained
in the bioengineering field, where different biomimetic matrices
have been developed. The full range of available materials,
natural, synthetic and semisynthetic (hybrid), have beenFrontiers in Immunology | www.frontiersin.org 5exploited in the form of hydrogels for their characteristics as a
suitable ECM support for tumor cell growth and their
autonomous self-assembly in tissue-like structures (Figure 2).
The detailed classification of the hydrogels, their applicability
and suitable processing approaches have been summarized by
Ullah and colleagues (51, 52). The main demands these materials
must satisfy are: i) provide proper cell alignment and attachment,
ii) sustain cellular metabolic activities, and iii) mimic cell
response to mechanical and chemical stimuli as in tissue (53).
The cells can be either seeded on the porous scaffold that
provides them with 3D support or encapsulated directly within
the biomaterials (cell-laden hydrogels) with well-defined stiffness
and viscosity. The most commonly used biomaterials for the
production of the scaffolds or cell-laden constructs are: collagen,
hyaluronic acid (HA), alginate, agarose, gelatin, fibrinogen
(natural); poly(lactic-co-glycolide) (PLGA), polyethylene glycol
(PEG), poloxamer 407 (Pluronic F127), and polycaprolactone
(PCL) (synthetic); and methacrylated gelatin (GelMA)
(semisynthetic) (54, 55). The choice is determined by the
tumor type and also by specific physical parameters such as
elasticity and stiffness (56). In this context, the ways in which
biomimetic matrices with different mechanical and biochemical
cues can determine the neuroblastoma cell phenotype have been
investigated, along with their contribution to the spatio-temporal
tumor cell organization or response to drugs. The excellent
reproducibility of the in vivo data has been demonstrated for
the neuroblastoma cell lines Kelly and their cisplatin resilient
counterpart (Cis83) when grown on different chemical
modifications of collagen, one with glycosaminoglycan
(Collagen-GAG) and the other with nanohydroxyapatite
(Collagen-nHA) (57). When treated with cisplatin, the cells
grown in 3D conditions show similarities with the PDX
(patient derived xenograft) treatment, while differing
substantially from their 2D control. This finding strengthens
the use of 3D models for initial drug evaluations since they more
closely approximate the expected response in vivo. Bacterial
nanocellulose scaffolds coated with collagen is another
approach that potentiates SH-SY5Y adhesion in 3D geometric
conditions (58). Physical support for neuroblastoma cell growth
is also provided by electrospun fibers used as 3D matrices (59).
Micro- and nano-fibers created by electrospinning guarantee
high porosity of the structures and favor neuroblastoma cell
proliferation and adhesion, while promoting neurite out-growth
(60). The usefulness of the highly aligned graphene-augmented
inorganic nanofiber (GAIN) scaffolds for biomedical cancer
research has also been proven for several tumor cell types
including neuroblastoma (61). Although they do not allow
tumor-like 3D cell organization entirely, these scaffolds open
an opportunity for a fast and highly reproducible validation of
anti-cancer drugs oriented toward the modulation of cell
migration. Another application of graphene is in the
fabrication of nanocomposite hydrogel scaffolds in which the
magnetic nanoparticle-decorated reduced-graphene oxide (m-
rGO) nanosheets lead to a unidirectional orientation of the cells
(62). This approach is particularly interesting in the models
where both cell orientation and the conductivity of theNovember 2020 | Volume 11 | Article 584214
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of growing neuroblastoma cells in collagen-based hydrogels
opens another prospect for achieving the 3D structures of
neuroblastoma for pre-clinical examinations. Collagen-based
structures also allow the reproduction of a 3D microenvironment
suitable for better comprehension of pro-migratory pathways
activated in neuroblastoma cells (27). Moreover, collagen-based
scaffolds offer possibilities for examination of the efficacy of a new
class of drugs known as migrastatics (64).
Neuroblastoma cells with different molecular backgrounds show
distinct patterns of growth inside biomimetic 3D structures.
Moreover, neuroblastoma cells can also be cultured in a mixture of
collagen and agarose that is often proposed in order to modify the
mechanical properties of pure collagen (65). The encapsulation of
neuroblastoma cells is as well supported by alginate and gelatin (66).
Either of the cast 3D platforms mentioned can be downscaled thus
opening the possibility of HTS applications. In fact, collagen
microencapsulation is a highly controllable approach for obtaining
miniaturized neuroblastoma tumors (67). In this nanofibrous
collagen meshwork, a reconstruction of the neuroblastoma
microenvironment is achieved thanks to the stromal cells’ support.
This study opens the possibility for using neuroblastoma cell-laden
bioinks for the reproduction of miniaturized tumors applying
different printing methodologies.Frontiers in Immunology | www.frontiersin.org 6(Bio)Printing Neuroblastoma 3D Models
Various 3D printing techniques have been employed to develop
more accurate constructs for cell-growth supports (68). Printing
technology is challenging the faithful reproduction of the tissue
compartments at the microscale while maintaining their unique
spatio-temporal organization (69). A parallel expansion of the
array of printable biomaterials compatible for research activities
or medical requirements has broadened the possibilities for 3D
printing (70). The inclusion of (bio)printing methodologies in
the neuroblastoma field has been considered in a few studies thus
far (Figure 3).
A mix of GelMA and methacrylated alginate (AlgMA) have
allowed the optimal mechanical properties and porosity for the
growth of neuroblastoma cells (71). Similar to the collagen-based
hydrogels, this printable bioink also permits tumor cells to organize
and create 3D architectures that very closely mimic human
neuroblastoma. An optimal level of stability upon printing is also
possible with chitosan-gelatin ink, which shows good
biocompatibility and allows the proper adhesion of
neuroblastoma cells. It is also easily manageable without the need
for additional processing post-printing, which makes it a good
candidate for high rate production of cell-laden hydrogels (72).
Different neuroblastoma cell lines have been explored using the
freeform reversible embedding of suspended hydrogel (FRESH)FIGURE 2 | Overview of different types of scaffolds explored for neuroblastoma studies. Left panel: Thermal sintering-based approach used for the fabrication of
cell-free (rigid) scaffolds with defined geometry. These scaffolds provide mechanical support for cell growth. Cell morphology and cell distribution inside the
interconnecting microchannels is directly influenced by the structure of the scaffold. Middle panel: Cast cell-laden hydrogels are used as the biomimetic ECM support
for the embedded cells. As an option, cells can be seeded on top of the pre-made hydrogel structure. Right panel: Printing (e.g. microextrusion, drop-on-demand,
laser-based printing) of various bioinks can be adopted for the scaffolding process. Both cellular and acellular approaches can be adopted for the generation of
porous scaffolds with defined spatial distribution of the bioink.November 2020 | Volume 11 | Article 584214
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study was designed for neurodegenerative diseases, the approach
and experimental design are incredibly attractive for analyzing
tumor cells within 3D conductive bioinks. The FRESH method
proves that high resolution of neuroblastoma 3D structures can be
obtained using low-viscosity liquids in a supporting bath of gelatin.
Neuroblastoma cells can be successfully grown in cellulose and
alginate-based hydrogels, demonstrating the applicability of FRESH
bioprinting for the generation of microsized 3D neuroblastoma
tumors (74). The same type of hydrogel has been explored in the
immunology field as well showing the changes in
immunophenotype profiles in neuroblastoma cells surrounded by
biomimetic ECM (75). Beta tricalcium phosphate (b-TCP) scaffolds
used as bone mimetic, have been obtained by combining high
resolution 3D printing with manually cast slurry (76). They have
been proposed as a suitable approach for sustaining neuroblastoma
cell growth inside the metastatic niche (24). In this manner, a local
microenvironment is guaranteed allowing the quiescence of tumor
stem cells. In this model, the stromal support has been confirmed as
a substantial factor in tumor cell organization along with the
geometry of the scaffolds. Although the model has not yet beenFrontiers in Immunology | www.frontiersin.org 7exploited for pre-clinical studies, it can be easily adapted for low/
medium scale of drug screening. The metabolic activities and cell
death ratio can be easily measured, while microscopy would require
special adaptation in the case of live-imaging acquisition.ENGINEERED PLATFORMS FOR
STUDYING TUMOR BIOLOGY,
IMMUNOLOGY AND DRUG EFFICACY
The aim of engineered disease models is to reproduce in vitro the
complexity of the pathological environment in order to gain a
better understanding of disease etiology and progression (77).
The model composition depends on the research objectives: the
more complex the phenomenon under investigation, the more
elaborate the model must be (78). In vitro cell modeling using
miniaturized bioreactors shows great advantages since they allow
the use of small volumes of reagents and low cell number, the
portability, design versatility and integration with existing
devices or platforms for HTS (79). To study the effects of aFIGURE 3 | Bioprinting process during in vitro 3D model generation. The steps include bioink preparation (cells embedded in biocompatible inks), 3D bioprinting
(three most commonly used printing techniques are presented), and drug screening. All the steps can be performed in automated manner.November 2020 | Volume 11 | Article 584214
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miniaturized optically accessible bioreactor (MOAB) has been
developed based on a prototype of Raimondi et al. (80). This
bioreactor is composed of three independent and magnetically
lockable culture chambers, each containing a polystyrene scaffold
assembled on the top surface of a main body structure. The
MOAB is provided with two magnets, located in the chambers
and in the main body, whose magnetic coupling ensures a
hydraulic seal during the perfusion of 3D constructs. This
magnetic seal generates a static magnetic field, which
influences cell functions including viability, metabolic activity
and gene expression. The MOAB device, specifically conceived to
study the influence of a static magnetic field on neuroblastoma
cell lines, might potentially be used as an in vitro model of
neurodegeneration to test perfused 3D cell constructs in terms of
response to different stimuli.
To reproduce neuroblastoma vasculogenic mimicry, a complex
in vitro model has been fabricated by culturing pre-vascularized
neuroblastoma cell sheets separated by fibrin layers in a perfusion
bioreactor. The cell sheets are prepared by co-culturing the
neuroblastoma cell line SK-N-BE(2) with human umbilical vein
endothelial cells (HUVEC) on temperature-responsive poly(N-
isopropylacrylamide) (PIPAAm)-grafted culture plates. A
collagen-gel base with microchannels is used as a support for the
vascular bed (81). This platform may represent an interesting
option for drug testing, especially for drugs exhibiting
antiangiogenic features. The fabrication of an intrinsic system of
vasculature allows a better mimicking of the native tumor while
augmenting predictive power for translation into pre-clinical
applications. However, the difficulty of cell-sheet fabrication and
stacking, together with the assembly of the collagen-gel base with
microchannels for the perfusion, represent a critical obstacle to a
large-scale application of this model.
Another step toward a model resembling native neuroblastomas
is represented by the 3D tetra-culture brain microphysiological
system (BMPS) used to test neurotoxic chemical agents. This system
is developed starting from the OrganoPlate (MIMETAS,
Netherlands) in which neuroblastoma cells (N2a), astrocytes (C8-
D1A) andmicroglia (BV-2) are cultured in a collagen type I solution
to recreate the brain parenchyma. The neurovascular environment
is assured by also including endothelial cells (bEnd.3). The entire
system requires culturing in perfusion conditions to permit
appropriate 3D cell organization. This plate-based microfluidic
platform may be applied for automated, high-throughput and
high-content imaging with relatively fast readouts (82).
Nevertheless, more consistent validations of their use for a routine
drug screening are mandatory.
Clinical Needs and Future Perspectives for
In Vitro Immunotherapy Evaluations
Immunotherapies have recently attracted great interest as a novel
approach for cancer treatment, but the lack of adequate in vitro
models for testing the efficacy of these therapies at a personalized
level is still an issue (75, 83). Immunotherapy strategies rely both, on
the ability of the immune system to kill malignant cells by
recognizing specific tumor antigens and the ability of tumor cellsFrontiers in Immunology | www.frontiersin.org 8to evade this physiological defense system.Twomajor strategies can
be identified: re-activation of the tumor infiltrating lymphocytes
(TILs) through the immune checkpoint inhibitors and chimeric
antigen receptor-T (CAR-T) or T cell receptor (TCR) cell therapy.
Checkpoint inhibitors work by blocking the inhibitory binding
between T cells’ checkpoint proteins (e.g. PD1) and their ligand on
tumor cells (e.g. PDL1), allowing the immune system to become
able once again to kill cancer (84). The CAR-T/TCR consists of the
patient’s T-cells genetically modified to express unique tumor
antigens that give them the ability to specifically target cancer
cells, such as GD2 for neuroblastoma (84, 85).
Currently, several types of immunotherapy are being studied for
use against neuroblastoma (86, 87) and complex in vitro 3D models
that will allow a close relationship between target and effectors as
occurs in vivo are needed for pre-clinical efficacy evaluation of
immunotherapeutics. As shown in Figure 4, immunotherapy
strategies can be developed and tested directly using patient
derived cells as part of a personalized medicine approach.
To test the migratory and lethality of TCR engineered patient-
derived T cells toward hepatic tumors, an interesting 3D in vitro
model has been developed by Pavesi and colleagues (83). This
model consists of a 3D microdevice made of a poly
(dimethylsiloxane) structure comprising a gel region with media
channels separated from the gel channel by trapezoidal posts.
Tumor cells are cultured embedded in a type I collagen gel
solution that is injected into the predefined gel region of the
device. The culture medium channels allow the cell culture
perfusion and the free movement of TCR-T cells from the
medium channel into the 3D solid collagen region containing
target cells. This 3D assay could lead to a better understanding of
what is encountered physiologically during adoptive T cell therapy
of solid tumors, where the chemotactic characteristics and intrinsic
killing of the engineered T cells are key factors in the successful
outcome of the therapy. Although this 3D microdevice has been
tested with human liver carcinoma cell line as its target, it could be
useful to study other solid tumors including neuroblastoma.
For functional in vitro prediction of the efficacy of checkpoint
inhibitors, a rapid functional test based on the use of the VITVO
device (Rigenerand srl, Italy) has been recently proposed. VITVO is
a small, portable bioreactor integrating a synthetic and
biocompatible fiber-based matrix, and can host several types of
cells, also in combination. Using this platform, primary cells
harvested from human lung cancer specimens have been
evaluated to predict the patient specific anti-tumor immunity of
TILs triggered by checkpoint inhibitor Nivolumab (88). The same
approach could also be considered to evaluate neuroblastoma
responsiveness to immunomodulatory agents. Although these in
vitro 3D platforms potentially offer innovative tools for the
development of fast and reliable personalized assays, further
studies are needed to confirm their relevance for clinical use.CONCLUSIONS
The more effective targeting of malignant cells remains a highly
challenging task since the existing therapeutics approaches do notNovember 2020 | Volume 11 | Article 584214
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when translated to clinical trial. The purpose of including 3D
tumor models is therefore to establish a new approach that
overcomes the limitations of currently used in vitro protocols
(Figure 5). The 3D in vitro models provide a closer reflection of
the complexity of malignant tissues by nurturing complex cell-cellFrontiers in Immunology | www.frontiersin.org 9and cell-ECM organization. Under these growth modalities, tumor
cells more closely approach their native interactions, generating
tumor-like structures that strongly define the types of response to
toxic drug insults. The number of possibilities for using
neuroblastoma 3D models in HTS is increasing thanks to
advances in bioengineering field. However, the automation ofFIGURE 4 | In vitro 3D models to test the efficacy of immunotherapeutics in a personalized approach strategy. On the left, the functional assay for cancer
responsiveness to checkpoint inhibitors using VITVO bioreactor described by Candini et al. (88); on the right, TCR T-cell activity against tumor using 3D microfluidic
device described by Pavesi and colleagues (83).FIGURE 5 | Current in vitro models. Advantages and limitations overview of current 3D in vitro models versus 2D systems are summarized.November 2020 | Volume 11 | Article 584214
Corallo et al. 3D In Vitro Neuroblastoma Modelsmultiparametric data extrapolation in terms of volumetric
parameters and cell viability within analyzed 3D structures
remains a challenge. The introduction of bioprinting processes in
pre-clinical studies is expected to bring to a greater reproducibility
of the cell models, as well as higher predictability and controllability
of the structures in comparison with the cast approach. The
precision and resolution of the cell-laden structure bioprinting
are determined by the characteristics of the nozzles, which do not
allow the printability of all currently available bioinks. Although
very useful, a limitation of using preformed porous scaffolds for
sequential cell plating and culturing is the poor reproducibility of
the spatio-temporally location of more than one cell type. The
combination of (bio)printing and fabrication of microfluidic
platforms in the field of neuroblastoma can therefore amplify the
possibilities for HTS in 3D conditions. It is particularly intriguing if
the described, versatile 3D cell culture systems could advance the
pre-clinical evaluation of newly proposed tailored therapies and
cell-based therapies that are currently under investigation for
defeating neuroblastoma tumor cells.Frontiers in Immunology | www.frontiersin.org 10AUTHOR CONTRIBUTIONS
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